News Conference News AHA 2025 Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV Michael O'Riordan November 08, 2025
News Conference News AHA 2024 Clues to Evolocumab Response Exist in Patients’ Genes: YELLOW III Caitlin E. Cox November 21, 2024
News Conference News AHA 2024 Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360 Michael O'Riordan November 18, 2024
News Conference News AHA 2023 Reductions in Plaque, Inflammation Appear to Explain Statin Benefit in HIV Todd Neale November 17, 2023
News Conference News AHA 2022 Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT Michael O'Riordan November 05, 2022
News Conference News AHA 2021 ApoB Gains Ground as Best Lipid Predictor of MI Risk Michael O'Riordan November 22, 2021
News Conference News AHA 2019 EVAPORATE Hints at Slowed Plaque Progression With Icosapent Ethyl Todd Neale November 18, 2019
Presentation AHA 2019 Effect of Icosapent Ethyl on Progression of Coronary Atherosclerosis in Patients With Elevated Triglycerides on Statin Therapy: The EVAPORATE Study Presenter: Matthew Budoff November 18, 2019
News Conference News AHA 2019 Inclisiran Slashes LDL in ASCVD Patients: ORION-10 Yael L. Maxwell November 16, 2019
News Conference News AHA 2019 COLCOT Renews Hope for Anti-inflammatory in Secondary Prevention: Colchicine Caitlin E. Cox November 16, 2019
News Conference News AHA 2018 Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT Michael O'Riordan November 10, 2018
News Conference News AHA 2017 Low-Dose Rivaroxaban Plus Aspirin Lowers Some Costs in COMPASS, but Full Economic Impact Unclear Todd Neale November 14, 2017
News Conference News AHA 2017 CANTOS: Big Drop in CVD Events Among Canakinumab Responders Michael O'Riordan November 13, 2017
News Conference News AHA 2016 PCSK9 Inhibition and Other New Therapies for Lipid Modification: Good News and Bad Michael O'Riordan November 15, 2016